Research programme: cancer therapeutics - Kineta Immuno Oncology

Drug Profile

Research programme: cancer therapeutics - Kineta Immuno Oncology

Alternative Names: KIN 131A; RIG-I like receptor - Kineta; RLR Agonist - Kineta

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kineta
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DDX58 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 05 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer released by Kineta
  • 22 Jan 2018 Kineta Immuno Oncology released pharmacodynamic data from preclinical trials in Cancer
  • 23 Mar 2017 Early research in Cancer in USA before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top